Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
14/05/2025 13:41
May 14 (Reuters) - Bluebird bio BLUE.O and Carlyle Group CG.O and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker. Shareholders may elect to receive either the new offer or the previous offer of $3 per share, with an additional $6.84 contingent upon bluebird achieving certain sales milestones. (Reporting by Puyaan Singh in Bengaluru' Editing by Anil D'Silva) ((Puyaan.Singh@thomsonreuters.com;))
Recent news on bluebird bio
See all newsBrief: Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital
Brief: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
Brief: Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment